A Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Randomised Study of ZD4054 Plus Carboplatin and Paclitaxel or Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy.

Trial Profile

A Phase II, Double-Blind, Placebo-Controlled, Multi-Centre, Randomised Study of ZD4054 Plus Carboplatin and Paclitaxel or Placebo Plus Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer Sensitive to Platinum-Based Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2013

At a glance

  • Drugs Zibotentan (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 06 Aug 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Actual patient number is 120 according to ClinicalTrials.gov.
    • 05 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top